357 related articles for article (PubMed ID: 27007129)
21. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
22. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
Serdjebi C; Milano G; Ciccolini J
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):665-72. PubMed ID: 25495470
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine in the treatment of ovarian cancer.
Hansen SW; Tuxen MK; Sessa C
Ann Oncol; 1999; 10 Suppl 1():51-3. PubMed ID: 10219453
[TBL] [Abstract][Full Text] [Related]
24. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
25. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Mercier C; Evrard A; Ciccolini J
J Clin Oncol; 2007 Oct; 25(30):4855; author reply 4855-6. PubMed ID: 17947739
[No Abstract] [Full Text] [Related]
26. Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.
Harris M; Bhuvaneshwar K; Natarajan T; Sheahan L; Wang D; Tadesse MG; Shoulson I; Filice R; Steadman K; Pishvaian MJ; Madhavan S; Deeken J
Pharmacogenet Genomics; 2014 Feb; 24(2):81-93. PubMed ID: 24401833
[TBL] [Abstract][Full Text] [Related]
27. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Celia C; Cosco D; Paolino D; Fresta M
Expert Opin Drug Deliv; 2011 Dec; 8(12):1609-29. PubMed ID: 22077480
[TBL] [Abstract][Full Text] [Related]
29. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine and UFT plus oral calcium folinate: phase I study.
Philip PA; Ibrahim D; Zalupski M; Arlauskas P; Shields A
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):116-9. PubMed ID: 10442378
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Sausville E; Lorusso P; Carducci M; Carter J; Quinn MF; Malburg L; Azad N; Cosgrove D; Knight R; Barker P; Zabludoff S; Agbo F; Oakes P; Senderowicz A
Cancer Chemother Pharmacol; 2014 Mar; 73(3):539-49. PubMed ID: 24448638
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF; Reitz J
Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine in the treatment of metastatic pancreatic cancer.
Hilbig A; Oettle H
Expert Rev Anticancer Ther; 2008 Apr; 8(4):511-23. PubMed ID: 18402518
[TBL] [Abstract][Full Text] [Related]
34. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
[TBL] [Abstract][Full Text] [Related]
35. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
Smorenburg CH; Sparreboom A; Bontenbal M; Verweij J
Eur J Cancer; 2001 Dec; 37(18):2310-23. PubMed ID: 11720823
[TBL] [Abstract][Full Text] [Related]
37. [Gemcitabine: from preclinic to clinic passing by pharmacokinetics].
Lokiec F; Lansiaux A
Bull Cancer; 2007; 94 Spec No Actualites():S85-9. PubMed ID: 17845976
[TBL] [Abstract][Full Text] [Related]
38. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.
Adjei AA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):30-4. PubMed ID: 12571808
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapies for pancreatic cancer--the role of pharmacogenetics.
Soo RA; Yong WP; Innocenti F
Curr Drug Targets; 2012 Jun; 13(6):811-28. PubMed ID: 22458528
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Ueno H; Kiyosawa K; Kaniwa N
Br J Cancer; 2007 Jul; 97(2):145-51. PubMed ID: 17595663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
